Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DBV Technologies (DBVT) Interest & Investment Income (2014 - 2019)

DBV Technologies (DBVT) reported Interest & Investment Income of $7789.1 for Q3 2019, down 98.6% year-over-year from $557138.9 in Q3 2018, and up 100.38% on a QoQ basis from -$2.1 million in Q4 2018.

DBV Technologies (DBVT) has 5 years of Interest & Investment Income data on file, last reported at $7789.1 in Q3 2019.

  • Quarterly Interest & Investment Income fell 98.6% year-over-year to $7789.1 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was -$1.5 million (down 189.33% YoY) and the FY2018 annual result came in at $562708.4, down 22.42% from the prior year.
  • Interest & Investment Income rose to $7789.1 in Q3 2019 per DBVT's latest filing, from -$2.1 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $577988.9 in Q2 2015 and bottomed at -$2.1 million in Q4 2018.
  • The 4-year median for Interest & Investment Income is $531041.3 (2016), against an average of -$75882.8.
  • The widest annual swing landed in 2015, when Interest & Investment Income climbed 28.05%; it then tumbled 98.6% in 2019.
  • Tracing DBVT's Interest & Investment Income over 4 years: stood at $577988.9 in 2015, then decreased by 8.12% to $531041.3 in 2016, then slumped by 486.67% to -$2.1 million in 2018, then surged by 100.38% to $7789.1 in 2019.
  • Per Business Quant, the three latest DBVT Interest & Investment Income figures stand at $7789.1 (Q3 2019), -$2.1 million (Q4 2018), and $557138.9 (Q3 2018).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 7.90 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 114.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - 305,000.00
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 26.60 Mn
10 DBV Technologies 8.00 Bn 7.77 Bn -3.90 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2019 7,789.11
Dec 31, 2018 -2.05 Mn
Sep 30, 2018 557,138.88
Jun 30, 2016 531,041.26
Jun 30, 2015 577,988.89
Jun 30, 2014 451,381.46